|
Christopher V. Plowe, MD, MPH
Associate Professor of Medicine
MD: Cornell University Medical College, 1986
M.P.H: Columbia University School of Public Health, 1991
Phone: (410) 706-2491
Fax: (410) 706-1204
E-mail: cplowe@medicine.umaryland.edu
Address:
Center for Vaccine Development
University of Maryland School of Medicine
685 W. Baltimore Street, HSF1-480
Baltimore, MD 21201
RESEARCH INTERESTS
Malaria drug resistance, molecular epidemiology, clinical trials.
Dr. Plowe is chief of the Malaria Section in the Center for Vaccine Development. His group studies the molecular mechanisms and molecular epidemiology of resistance to antimalarial drugs, particularly the antifolate drugs and chloroquine. Plasmodium falciparum resistant to these drugs is already widespread in much of South America and Asia, and chloroquine resistance is responsible for large increases in malaria morbidity and mortality in parts of Africa. Dr. Plowe's team has developed rapid molecular assays for parasite mutations that cause the parasite to be resistant to specific drugs. Validating molecular assays for drug resistant malaria, transferring these technologies to laboratories in malaria endemic areas, and applying the assays for malaria control have been a major focus of Dr. Plowe's program. In collaboration with colleagues at the University of Mali, Dr. Plowe has also developed a field research site in the Dogon Country of Mali in West Africa. This field station is the site of studies of drug resistance, the human immune response to malaria and the pathogenesis of severe malaria, all in preparation for malaria vaccine trials. His team conducted the first malaria vaccine trial in Mali in Bandiagara in 2003-2004 and began another in late 2004. The Malaria Section also has a research program in Blantyre, Malawi in Central Africa, where the focus is on drug resistant malaria and clinical trials of malaria drugs.
RECENT PUBLICATIONS
Djimde AA, Dolo A, Ouattara A, Diakite S, Plowe CV, Doumbo OK. Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones. Journal of Infectious Diseases. 2004;190:853-5
Plowe CV, Kublin JG, Dzinjalamala FK, Kamwendo DS, Mukadam RA, Chimpeni P, Molyneux ME, Taylor TE. Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. British Medical Journal. 2004;328:545-9
Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y,
Niare-Doumbo S, Coulibaly D, Kone AK, Cissoko Y, Tekete M, Fofana B, Dicko A, Diallo DA, Wellems TE, Kwiatkowski D, Plowe CV. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene. 2003;69:558-63
Plowe CV. Monitoring antimalarial drug resistance: making the most of the tools at hand. Journal of Experimental Biology. 2003;206:3745-52
Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. Journal of Infectious Diseases. 2003;187:1870-5
 Back to Secondary Faculty
To contact us:
Phone: 410-706-7560
Fax: 410-706-4619
E-mail: kvardjan@ihv.umaryland.edu
 Back to Top of Page
|
